[A Case of Successful Hepatic Resection of Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab for Recurrent Liver and Lung Metastases].
{"title":"[A Case of Successful Hepatic Resection of Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab for Recurrent Liver and Lung Metastases].","authors":"Kenta Shiraishi, Daisuke Suzuki, Koya Fujii, Tsukasa Takayashiki, Shigetsugu Takano, Nozomu Sakai, Isamu Hosokawa, Takashi Mishima, Takanori Konishi, Hitoe Nishino, Kensuke Suzuki, Shinichiro Nakada, Masayuki Ohtsuka","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Drug therapy for hepatocellular carcinoma has made remarkable progress in recent years, and surgical resection of tumors that respond well to drug therapy has been performed in some cases. We report a case of hepatocellular carcinoma with hepatopulmonary metastases that was successfully treated with atezolizumab plus bevacizumab and surgically resected. The patient was a 56-year-old man who underwent a posterior segmentectomy and was diagnosed with hepatocellular carcinoma. Three months after the surgery, CT revealed multiple liver and lung metastases. Fifteen courses of atezolizumab and bevacizumab were administered. Drug therapy was effective, and most metastases disappeared; however, the liver metastasis remained in segment 8/4, and partial resection of the liver was performed. Recurrence was observed in liver segment 2 after 1 year and 2 months, and partial resection of the liver was performed. The patient is currently alive and recurrence-free 3 months after the surgery. With progress in drug therapy, multimodal treatment for unresectable hepatocellular carcinoma is expected to improve the prognosis.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 2","pages":"173-175"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Cancer and Chemotherapy","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Drug therapy for hepatocellular carcinoma has made remarkable progress in recent years, and surgical resection of tumors that respond well to drug therapy has been performed in some cases. We report a case of hepatocellular carcinoma with hepatopulmonary metastases that was successfully treated with atezolizumab plus bevacizumab and surgically resected. The patient was a 56-year-old man who underwent a posterior segmentectomy and was diagnosed with hepatocellular carcinoma. Three months after the surgery, CT revealed multiple liver and lung metastases. Fifteen courses of atezolizumab and bevacizumab were administered. Drug therapy was effective, and most metastases disappeared; however, the liver metastasis remained in segment 8/4, and partial resection of the liver was performed. Recurrence was observed in liver segment 2 after 1 year and 2 months, and partial resection of the liver was performed. The patient is currently alive and recurrence-free 3 months after the surgery. With progress in drug therapy, multimodal treatment for unresectable hepatocellular carcinoma is expected to improve the prognosis.